These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Wärnberg F, Nordgren H, Bergkvist L, Holmberg L. Br J Cancer; 2001 Sep 14; 85(6):869-74. PubMed ID: 11556839 [Abstract] [Full Text] [Related]
5. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Anticancer Res; 2005 Sep 14; 25(3A):1719-23. PubMed ID: 16033090 [Abstract] [Full Text] [Related]
6. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. Vos CB, Ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ. J Pathol; 1999 Feb 14; 187(3):279-84. PubMed ID: 10398079 [Abstract] [Full Text] [Related]
7. Different proliferative patterns characterize different preinvasive breast lesions. Viacava P, Naccarato AG, Bevilacqua G. J Pathol; 1999 Jul 14; 188(3):245-51. PubMed ID: 10419590 [Abstract] [Full Text] [Related]
8. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. Gillett CE, Lee AH, Millis RR, Barnes DM. J Pathol; 1998 Apr 14; 184(4):396-400. PubMed ID: 9664905 [Abstract] [Full Text] [Related]
9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL. APMIS Suppl; 2003 Apr 14; (108):1-67. PubMed ID: 12874968 [Abstract] [Full Text] [Related]
10. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C. Histopathology; 2005 May 14; 46(5):561-8. PubMed ID: 15842638 [Abstract] [Full Text] [Related]
14. Is there 'progression through grade' in ductal invasive breast cancer? Schymik B, Buerger H, Krämer A, Voss U, van der Groep P, Meinerz W, van Diest PJ, Korsching E. Breast Cancer Res Treat; 2012 Oct 14; 135(3):693-703. PubMed ID: 22886478 [Abstract] [Full Text] [Related]
15. Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Ellsworth RE, Vertrees A, Love B, Hooke JA, Ellsworth DL, Shriver CD. Ann Surg Oncol; 2008 Sep 14; 15(9):2519-25. PubMed ID: 18622645 [Abstract] [Full Text] [Related]
16. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Naidu R, Wahab NA, Yadav MM, Kutty MK. Oncol Rep; 2002 Sep 14; 9(2):409-16. PubMed ID: 11836618 [Abstract] [Full Text] [Related]
20. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Mod Pathol; 2002 Feb 14; 15(2):116-24. PubMed ID: 11850540 [Abstract] [Full Text] [Related] Page: [Next] [New Search]